About Us

Our Values

Zeal
Passion to positively impact the lives of patients through compassion, excellence in product quality, affordability and marketability

Innovation
Challenge status quo to enhance value-providing attributes of our products and processes

Partnerships
Build strong and enduring partnerships that enable the success of our Customers, based on value enhancement, mutual respect, trust and transparency

Performance
Strive to deliver performance that enables our customers to win in the marketplace. Continuously upgrade our skills and drive change to do so

Teamwork
Be a strong team player through respect, trust, care, kindness and transparency

Integrity
Be fair, honest, transparent and ethical in our conduct

Care for environment
Judiciously use and protect resources, minimize waste and leave a better place for our future generations

ZIM Labs has technology backed solutions that cater to various therapeutic segments such as:

Cardiovascular
Anti-infective
Gastrointestinal
Respiratory system
Nervous system
Musculoskeletal
Hematology
Vitamins
Nutritional Deficiency

Our innovative technology solutions include drug release profile modifications, solubility & stability enhancement, taste masking and dosage form transformation

VALUE ADDITION

We offer our customers with a comprehensive range of value-added solid dosage and differentiated generic products in semi-finished and finished categories/formulations. These include granules, pellets (sustained, modified, extended-release), taste-masked powders, suspensions, tablets, capsules and its recently developed Oral Thin Films (OTF).

GEOGRAPHICAL EXPANSION

We use our proprietary knowledge, technology and manufacturing process expertise to bridge the technology gap in Tier III Pharmerging & ROW markets while assisting local players in various geographies to launch differentiated / combination generic products and compete.

History & Path Forward

An overview of ZIM Labs at a glance from its inception, current offerings to its path forward and the leadership behind the journey.

Technology
Milestones
Business
Milestones

1989

Company and first manufacturing site establish

1993

WHO GMP Status and maiden public issue

2000

Pellets Technology developed

2005

Taste Masking Technology Introduced

2010

New Cephalosporin Block Added

2013

New Orally Disintegrating Strip (ODS) Manufacturing Block Added

2014

WHO-GMP Status for Orally Disintegrating Strip Mfg. Facility

2015

EU GMP Accreditation

2018

EU GMP Audit Cleared Successfully by "EUGMP Re-Accredited"

2000

Leading supplier of pharmaceutical products to government organizations through tenders from its WHO-GMP approved plant

2001-12

Developed pellets, granules and taste masking technology platforms to change its focus to differentiated and higher margin products
Ventured into international markets in middle east and North Africa (MENA)
Established ‘Proof-of-Concept’ for oral thin films and nano-technology

2012-17

Focus on higher margin businesses
Reduced deemed export and low margin government business
Upgraded its manufacturing facilities to EU-GMP standards
Investment in team and processes
Invested in separate WHO-GMP approved OTF facility and commercialised OTF products
Entered into newer geographies like SEA, Latin America, CIS and Africa and grew Sri Lanka, Bangladesh and MENA
Focused on building a steady pipeline with dossier filings and own product registrations

2018-20

ZIM Laboratories Limited got listed on Bombay Stock Exchange, Continued focus in core PFI business through new geographies, new customer relationships and new product pipeline for its business partners
Growing its niche generic formulations business – through registration, marketing partnerships and continued launch of products in MENA, SE Asia, Latin America and CIS countries (as demonstrated in Sri Lanka)
Launch of OTF (prescription and OTC products) as an alternate drug delivery platform across RoW / Emerging Markets and Regulated Markets
Invest in R&D to develop a pipeline of products with focus on developed markets and enhance capacity and flexibility by appropriate capex

Focus on the NDDS Segment

Over time ZIM Labs has created a long term sustainable advantage by focusing on Novel Drug Delivery Solutions (NDDS) segment through continuous innovation and development of non-infringing technology platforms and the supply of high-quality products at competitive prices

Unique Business Model

R&D capabilities & manufacturing skills to develop & supply differentiated generic products, in pre-formulation dosage forms, to business partners who need comprehensive support in product development, full manufacturing technical training, registration & sourcing of such differentiated products to boost their pipeline & compete.

Innovative & Differentiated Product Portfolio

ZIM Labs supplies a wide range of solid dosage differentiated products across various therapeutic segments. ZIM Labs is a pioneer in the OTF technology in India and focused on growing this platform in partnership with marketing companies and product originators.

Extensive R&D Capabilities

ZIM Labs has a state-of-the-art R&D center with a team of over 90 professionals. ZIM Labs is now setting up a new R&D center with a team, equipment and capabilities targeted for developed markets.

Technocrat Promoter & Professional Management

The Company is led by an experienced technocrat who is supported by a well-qualified professional management team.

State-of-the-Art Manufacturing Setup

ZIM Labs has three manufacturing blocks (General, Cephalosporin and OTF). ZIM Labs general block is EU-GMP and WHO-GMP approved. Its Cephalosporin and OTF blocks are WHO-GMP approved. ZIM Labs is amongst the few companies in India to receive WHO-GMP approval for its OTF facility.

Multi-Pronged Growth Strategy

Developing new technology platforms & differentiated generic products for itself and under license arrangement. Manufacturing and supply of finished and semi-finished formulations for RoW. Development of the Thin Film as an alternate delivery platform.

Robust Financials

The Company has improved its EBITDA Margin from 11% to 15% in the last four years on account of continued focus on high margin businesses.

Accreditations

Our facilities are accredited with worthy certifications from authorized independent bodies, which are generally accepted worldwide as a mark of approval of quality of manufacturer’s operational capabilities. These accreditations are: